RETRACTED ARTICLE: The influence of a balanced volume replacement concept on inflammation, endothelial activation, and kidney integrity in elderly cardiac surgery patients

PurposeA balanced fluid replacement strategy appears to be promising for correcting hypovolemia. The benefits of a balanced fluid replacement regimen were studied in elderly cardiac surgery patients.MethodsIn a randomized clinical trial, 50 patients aged >75 years undergoing cardiac surgery received a balanced 6% HES 130/0.42 plus a balanced crystalloid solution (n = 25) or a non-balanced HES in saline plus saline solution (n = 25) to keep pulmonary capillary wedge pressure/central venous pressure between 12–14 mmHg. Acid-base status, inflammation, endothelial activation (soluble intercellular adhesion molecule-1, kidney integrity (kidney-specific proteins glutathione transferase-alpha; neutrophil gelatinase-associated lipocalin) were studied after induction of anesthesia, 5 h after surgery, 1 and 2 days thereafter. Serum creatinine (sCr) was measured approximately 60 days after discharge.ResultsA total of 2,750 ± 640 mL of balanced and 2,820 ± 550 mL of unbalanced HES were given until the second POD. Base excess (BE) was significantly reduced in the unbalanced (from +1.21 ± 0.3 to −4.39 ± 1.0 mmol L−1 5 h after surgery; P < 0.001) and remained unchanged in the balanced group (from 1.04 ± 0.3 to −0.81 ± 0.3 mmol L−1 5 h after surgery). Evolution of the BE was significantly different. Inflammatory response and endothelial activation were significantly less pronounced in the balanced than the unbalanced group. Concentrations of kidney-specific proteins after surgery indicated less alterations of kidney integrity in the balanced than in the unbalanced group.ConclusionsA total balanced volume replacement strategy including a balanced HES and a balanced crystalloid solution resulted in moderate beneficial effects on acid-base status, inflammation, endothelial activation, and kidney integrity compared to a conventional unbalanced volume replacement regimen.

[1]  M. Mitsnefes,et al.  Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. , 2003, Journal of the American Society of Nephrology : JASN.

[2]  J. Mcgiff,et al.  Chloride anion concentration as a determinant of renal vascular responsiveness to vasoconstrictor agents , 1993, British journal of pharmacology.

[3]  J. Kellum.  Saline-induced hyperchloremic metabolic acidosis. , 2002, Critical care medicine.

[4]  X. Leverve,et al.  Half-molar sodium-lactate solution has a beneficial effect in patients after coronary artery bypass grafting , 2008, Intensive Care Medicine.

[5]  J. Waitzinger,et al.  Pharmacokinetics and Tolerability of a New Hydroxyethyl Starch (HES) Specification [HES (130/0.4] after Single-Dose Infusion of 6% or 10% Solutions in Healthy Volunteers , 1998, Clinical drug investigation.

[6]  H. Karamanoukian,et al.  Good outcomes from cardiac surgery in the over 70s , 2000, Heart.

[7]  B. Gustorff,et al.  The Effects of Hydroxyethyl Starches of Varying Molecular Weights on Platelet Function , 2001, Anesthesia and analgesia.

[8]  E. Base,et al.  Comparison of 6% HES 130/0.4 in a balanced electrolyte solution versus 6% HES 130/0.4 in saline solution in cardiac surgery , 2006, Critical Care.

[9]  P. Glass,et al.  Hextend, a physiologically balanced plasma expander for large volume use in major surgery: a randomized phase III clinical trial. Hextend Study Group. , 1999, Anesthesia and analgesia.

[10]  Jeana E. Havidich,et al.  Why the Food and Drug Administration changed the warning label for hetastarch. , 2004, Anesthesiology.

[11]  W. White,et al.  Acute renal failure following cardiac surgery. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  E. Bennett-Guerrero,et al.  Hydroxyethyl Starch in Balanced Electrolyte Solution (Hextend®)—Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers , 2002, Anesthesia and analgesia.

[13]  R. Grounds,et al.  Improving post-operative morbidity and mortality , 2002 .

[14]  B. Phillips-Bute,et al.  Hextend[registered sign], a Physiologically Balanced Plasma Expander for Large Volume Use in Major Surgery: A Randomized Phase III Clinical Trial , 1999 .

[15]  E. Bennett-Guerrero,et al.  A Head-to-Head Comparison of the In Vitro Coagulation Effects of Saline-Based and Balanced Electrolyte Crystalloid and Colloid Intravenous Fluids , 2006, Anesthesia and analgesia.

[16]  Rolf Rossaint,et al.  Intensive insulin therapy and pentastarch resuscitation in severe sepsis. , 2008, The New England journal of medicine.

[17]  C. Wiedermann.  Hydroxyethyl starch – can the safety problems be ignored? , 2004, Wiener klinische Wochenschrift.

[18]  J. Bonventre,et al.  Biologic markers for the early detection of acute kidney injury , 2004, Current opinion in critical care.

[19]  J. Boldt.  Pro: use of colloids in cardiac surgery. , 2007, Journal of cardiothoracic and vascular anesthesia.

[20]  S. Kozek-Langenecker,et al.  Effects of Hydroxyethyl Starch Solutions on Hemostasis , 2005, Anesthesiology.

[21]  J. Kellum,et al.  Hyperchloremic acidosis increases circulating inflammatory molecules in experimental sepsis. , 2006, Chest.

[22]  R. Zander.  INFUSION FLUIDS: WHY SHOULD THEY BE BALANCED SOLUTIONS? , 2006 .

[23]  A. Webb,et al.  The rational administration of colloids. , 1993, Blood reviews.

[24]  J. Avorn,et al.  Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery. , 2003, Kidney international.

[25]  G. Nuttall,et al.  Con: use of colloids in cardiac surgery. , 2007, Journal of cardiothoracic and vascular anesthesia.

[26]  Robyn Norton,et al.  A comparison of albumin and saline for fluid resuscitation in the Intensive Care unit , 2005 .

[27]  T. Kotchen,et al.  Effect of chloride on renin and blood pressure responses to sodium chloride. , 1983, Annals of internal medicine.

[28]  C. Wilcox.  Regulation of renal blood flow by plasma chloride. , 1983, The Journal of clinical investigation.

[29]  J. Boldt,et al.  A total balanced volume replacement strategy using a new balanced hydoxyethyl starch preparation (6% HES 130/0.42) in patients undergoing major abdominal surgery , 2007, European journal of anaesthesiology.

[30]  E. Thervet,et al.  Hydroxyethylstarch and osmotic-nephrosis- like lesions in kidney transplantation , 1993, The Lancet.

[31]  G. Hill.  Cardiopulmonary bypass-induced inflammation: is it important? , 1998, Journal of cardiothoracic and vascular anesthesia.

[32]  G. Mills.  Hydroxyethyl starch: does our choice of colloid prevent or add to renal impairment? , 2007, British journal of anaesthesia.

[33]  B. Phillips-Bute,et al.  Hextend (R), a physiologically balanced plasma expander for large volume use in major surgery: A randomized phase III clinical trial , 1999 .

[34]  S. Mallett,et al.  The Effects of Balanced Versus Saline-Based Hetastarch and Crystalloid Solutions on Acid-Base and Electrolyte Status and Gastric Mucosal Perfusion in Elderly Surgical Patients , 2001, Anesthesia and analgesia.

[35]  L. Rink,et al.  Altered cytokine production in the elderly , 1998, Mechanisms of Ageing and Development.

[36]  T. Neff,et al.  Pharmacokinetics of Hydroxyethyl Starch , 2005, Clinical pharmacokinetics.